06), while on day 5 it was 107 8 for controls and 101 6 for vacci

06), while on day 5 it was 107.8 for controls and 101.6 for vaccinated animals (Wilcoxon rank-sum test P = 0.05). The vaccinated animals remained positive by RT-PCR on subsequent days post-challenge and some animals that were negative produced a positive result on later samples. By day 21, vaccinated horses were still positive by RT-PCR although infectious virus was undetectable by the end-point dilution assay. As expected, all four animals vaccinated with MVA-VP2(9) developed VNAb by the time of challenge with titres ranging between 1.6 to 2.4 (Table 3). Following AHSV-9 challenge these VNAb titres

increased more than four-fold in all four animals and the final titres Libraries recorded on day 28 post-challenge reached values of between 2.3 to more than 3.1. All non-vaccinated control horses were

negative for VNAb at virus challenge selleck inhibitor and did not develop VNAb before they succumbed to AHSV-9 infection. Antibodies to AHSV-VP7 were detected in serum samples of Obeticholic Acid the vaccinated horses only after challenge (Table 4). As expected all horses were negative by the VP-7 ELISA test on the day of challenge (day 34). This study in the disease relevant host, the horse, was aimed at determining the protective capacity of vaccines based onMVA-VP2 against virulent AHSV challenge. This work focused on AHSV-9. Thus, the MVA-VP2(9) recombinant vaccine was constructed using the genome segment encoding VP2 from the AHSV-9 reference strain (PAKrrah/09) and vaccinated animals were Bay 11-7085 challenged with the AHSV-9 strain KEN/2006/01.

Ponies immunised with MVA-VP2(4) in a previous study [13] and those vaccinated with MVA-VP2(9) in this study developed VNAb titres after two doses and reached titres against homologous virus, ranging between 1.8 to 1.9 or between 1.6 to 2.4, respectively. These results are in line with studies by others using poxvirus vectors expressing AHSV-VP2. Thus, horses vaccinated with 107.1 TCID50 of a canarypox-based AHSV vaccine [14] expressing VP2 and VP5 developed serum VNAb titres of 20–40 (1.3–1.6 log10); and use of a recombinant vaccinia virus (strain WR) expressing AHSV-4 VP2 also induced VNAb in horses [20], albeit at low titres and only after 3 vaccine inoculations. In this study, vaccination of horses with MVA-VP2(9) showed very high levels of protection despite the high challenge virus dose used. Clinical signs were completely absent in vaccinates and the rectal temperatures were within normal physiological ranges during the study period. In contrast, the control horses experienced a peracute AHSV cardiac syndrome accompanied by high rectal temperatures. Vaccinated animals were also completely protected against viraemia as measured by a standard end-point dilution assay demonstrating the potential of MVA-VP2 vaccination to prevent onward transmission by the insect vectors.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>